UBS Starts Covance (CVD) at Neutral
More News related to CVD
- Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
- Covance to Present at the Credit Suisse 2008 Healthcare Conference
- David Moenning's Daily State of the Markets: 10/23
- Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2008 Financial Results Conference Call
- Covance (CVD) Reports In-Line Q3 EPS of $0.80
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
UBS initiates coverage on Covance (NYSE: CVD) with a Neutral rating.
Covance, Inc., a drug development services company, provides early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries worldwide.
Related Categories
New CoverageStocks Mentioned
-3.37Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
